Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.

NCT Number	NCT07227285
Lead Sponsor	Cyllene Therapeutics
Conditions	Urinary Bladder, Overactive, Spinal Cord Injury
Enrollment	16 participants
Start Date	2026-04
Primary Completion	2031-04 (estimated)
Study Completion	2031-04 (estimated)
Updated on ClinicalTrials.gov	2025-11-12